Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States

被引：0
作者：
Milev, S. [1 ]
Pohl, G. M. [2 ]
Sun, A. [1 ]
Mason, O. [2 ]
Njuguna, N. [2 ]
Loo, L. [2 ]
机构：
[1] Evidera Inc, San Francisco, CA USA
[2] Eli Lilly, Indianapolis, IN USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [31] Lasmiditan (200 Mg and 100 Mg) Compared to Placebo for Acute Treatment of Migraine
    Kuca, B.
    Wietecha, L.
    Berg, P.
    Aurora, S. K.
    HEADACHE, 2017, 57 (08): : 1311 - 1312
  • [32] Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response toTriptan Therapy
    Knievel, Kerry
    Lombard, Louise
    Buchanan, Andrew
    Baygani, Simin K.
    Raskin, Joel
    Tobin, Joshua
    NEUROLOGY, 2019, 92 (15)
  • [33] THE BUDGET IMPACT OF ZANUBRUTINIB FOR THE TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Campbell, D.
    Zimmerman, T.
    Migliaccio-Walle, K.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (07) : S430 - S431
  • [34] Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis
    Maiti, Rituparna
    Mishra, Archana
    Puliappadamb, Haridas Mundot
    Jena, Monalisa
    Srinivasan, Anand
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (12) : 1534 - 1544
  • [35] Phase 3 Study (SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Case, Michael G.
    Selzler, Katherine J.
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 367 - 368
  • [36] Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
    Anderson, Christopher C.
    VanderPluym, Juliana H.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 1979 - 1993
  • [37] Prior migraine treatments among patients initiating rimegepant for acute migraine treatment in the United States
    Brown, J.
    Jenkins, A.
    Blakeman, Hygge K.
    Lipton, R.
    HEADACHE, 2023, 63 : 74 - 74
  • [38] PHASE 3 STUDY (SPARTAN) OF LASMIDITAN COMPARED TO PLACEBO FOR ACUTE TREATMENT OF MIGRAINE
    Wietecha, L. A.
    Kuca, B.
    Case, M. G.
    Selzler, K. J.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 57 - 58
  • [39] Lasmiditan (200 mg and 100 mg) compared to placebo for acute treatment of migraine
    Kuca, Bernice
    Wietecha, Linda
    Berg, Paul H.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [40] The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research
    Burton, Wayne N.
    Landy, Stephen H.
    Downs, Kristen E.
    Runken, M. Chris
    MAYO CLINIC PROCEEDINGS, 2009, 84 (05) : 436 - 445
12345